BRAF and melanoma: Nonetheless, 17-AAG inhibited melanoma cell proliferation regardless of BRAF mutational status [18], perhaps due to these cells’ dependence upon CRAF signaling in melanomas with activating NRAS mutations [11] as well as activation of CRAF by BRAFWT under these conditions [19].